Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

luminarie group limited - melphalan hydrochloride 11.1946 mg/ml equivalent to melphalan 10 mg - powder for injection - 50 mg - active: melphalan hydrochloride 11.1946 mg/ml equivalent to melphalan 10 mg excipient: hydrochloric acid povidone water for injection ethanol propylene glycol sodium citrate dihydrate water for injection - melphalan injection, administered by regional arterial perfusion, is indicated in the treatment of: - localised malignant melanoma of the extremities; - localised soft tissue sarcoma of the extremities.

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - melphalan 2mg - film coated tablet - 2 mg - active: melphalan 2mg excipient: colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry white ys-1-18097-a

Armenia - Inggris - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

excella gmbh & co.kg - melphalan - tablets film-coated - 2mg

Malaysia - Inggris - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

aspen medical products malaysia sdn bhd - melphalan -

Armenia - Inggris - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

excella gmbh & co.kg - melphalan - tablets film-coated - 2mg

Singapura - Inggris - HSA (Health Sciences Authority)

dch auriga singapore - melphalan - tablet, film coated - 2.00 mg - melphalan 2.00 mg

Amerika Serikat - Inggris - NLM (National Library of Medicine)

oncopeptides, ab - melphalan flufenamide hydrochloride (unii: 3412470a0v) (melphalan flufenamide - unii:f70c5k4786) - pepaxto is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one cd38-directed monoclonal antibody. this indication is approved under accelerated approval based on response rate. continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) [see clinical studies (14)] . limitations of use pepaxto is not indicated and is not recommended for use as a conditioning regimen for transplant outside of controlled clinical trials [see warnings and precautions (5.5)]. pepaxto is contraindicated in patients with a history of serious hypersensitivity reaction to melphalan flufenamide or melphalan [see adverse reactions (6.1)] . risk summary based on its mechanism of action [see clinical pharmacology (12.1)] , pepaxto ca